Skip to content

South Korea approves Phase 2/3 trials of Celltrion COVID-19 antibody drug

September 17, 2020

South Korea said on Thursday it has approved Celltrion Inc’s experimental COVID-19 treatment for Phase 2/3 clinical trials, as the firm plans to seek a conditional approval of the antibody drug for an emergency use.

Celltrion has said it would begin commercial production of the drug, CT-P59, this month – likely to amount to around 1 million doses, in anticipation of demand in Korea and overseas.

The treatment, the most advanced antibody drug in terms of research in South Korea, is directed against the surface of the virus and designed to block it from locking on to human cells.

The Ministry of Food and Drug Safety said safety and efficacy of the drug were shown in the early stage of a trial, and a Phase 2/3 study will be offered to 1,020 participants.

Other companies developing potential COVID-19 treatments include Eli Lilly and Co, Regeneron Pharmaceuticals Inc and AbbVie.

Celltrion said human trials of the treatment will be carried out in 12 countries including Britain, Spain and the United States, and it anticipates primary results by the end of the year.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: